• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Biondvax Pharma ADR (NQ: BVXV )

    N/A UNCHANGED
    Last Price Updated: 3:59 PM EDT, Sep 6, 2023 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open -
    Bid (Size) 1.250 (3)
    Ask (Size) 1.380 (2)
    Prev. Close 1.360
    Today's Range N/A - N/A
    52wk Range N/A - N/A
    Shares Outstanding 461,285,824
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    BC Study Uncovers Cause of Four Major Pediatric Allergies
    Via Investor Brand Network
    BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Rebrands as Scinai Immunotherapeutics Ltd.
    Via Investor Brand Network

    Performance

    More News

    Read More
    BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd. to Reflect New Focus on Development of Novel Inflammation and Immunology (I&I) Biological Therapeutics
    From BiondVax Pharmaceuticals Ltd.
    Via GlobeNewswire
    BioMedNewsBreaks — BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Positioned Favorably with Worldwide License to Anti-IL-17 NanoAbs
    Via Investor Brand Network
    Exposures Product Safety
    Malaria Case Prompts Army to Ask Infectious Disease Experts to Analyze Mosquitoes
    Via Investor Brand Network
    England Sees Soaring Numbers of Hospitalizations for Severe Allergies
    Via Investor Brand Network
    BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Is Fast on the Trail to Target IL-17
    Via Investor Brand Network
    How Allergy Sufferers Can Benefit from Immunotherapy
    Via Investor Brand Network
    Analyzing Link Between Hormonal Contraceptives, Autoimmunity
    Via Investor Brand Network
    BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Advances NanoAb Therapy as IL-17 Drug Candidate for Psoriasis Treatment
    Via Investor Brand Network
    BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Q2 Financial Report, Corporate Update
    Via Investor Brand Network
    Stem Cell Transplants Followed by Immunotherapy Show Efficacy Against Pediatric Nerve Tumors
    Via Investor Brand Network
    BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) Alpaca-Derived Nanobodies for Potential Treatment of Diseases Underserved by Current Therapeutics
    Via Investor Brand Network
    Exposures COVID-19
    BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Q2 Financial Report, Corporate Update
    Via Investor Brand Network
    Exposures COVID-19
    BiondVax Reports Second Quarter Financial Results and Provides Business Update
    From BiondVax Pharmaceuticals Ltd.
    Via GlobeNewswire
    How Immunotherapy Outcomes Can Be Affected by Diet, Gut Microbiota
    Via Investor Brand Network
    Study Finds Link Between Food Allergies in Infants, Childhood Asthma Onset
    Via Investor Brand Network
    BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Granted Extension to Regain NASDAQ Compliance
    Via Investor Brand Network
    Exposures COVID-19
    Nasdaq Grants BiondVax Extension to Regain Compliance with Listing Rules
    From BiondVax Pharmaceuticals Ltd.
    Via GlobeNewswire
    BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Leveraging Unique NanoAb Pipeline to Target Large, Growing Markets
    Via Investor Brand Network
    Review Shows AI Could Be Pivotal in Infectious Disease Prevention
    Via Investor Brand Network
    Topics Artificial Intelligence
    Exposures Artificial Intelligence COVID-19
    M&A Activity, Booming Sales of Anti-IL-17 Drugs Suggest Strong Upside Potential for BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV)
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) CDMO Services Designed to Meet Needs of Pharmaceutical, Biotechnology Companies of All Sizes
    Via Investor Brand Network
    Exposures COVID-19
    Psoriasis Could Be Behind Frequent Fatigue
    Via Investor Brand Network
    BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) CEO Amir Reichman Featured on IBN’s The Bell2Bell Podcast
    Via Investor Brand Network
    Exposures COVID-19
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.